Berinert Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Berinert market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

Market growth during the historical period can be attributed to factors such as strong clinical evidence supporting efficacy, government funding, insurance support, strategic partnerships, and increased spending in the healthcare sector.

Growth during the market's forecast period is expected to be driven by evolving treatment guidelines, increased research and development, market expansion, strong physician advocacy, and advancements in genetic research. Key trends for the forecast period include the rise of prophylactic treatments, the shift toward home-based treatment options, expansion into emerging markets, the development of new inhibitors, and a growing focus on non-intravenous (IV) treatment options.

The increasing prevalence of genetic disorders is anticipated to drive the growth of the berinert market in the coming years. Genetic disorders are conditions caused by abnormalities in an individual's DNA, which may result from mutations in single or multiple genes, chromosomal changes, or a combination of genetic and environmental factors. The rising incidence of genetic disorders is attributed to factors such as greater environmental exposure, advancements in genetic testing, shifts in reproductive trends, increased awareness, and lifestyle influences. Berinert is used to treat hereditary angioedema (HAE), a genetic condition, by providing a C1 esterase inhibitor to help prevent and manage acute swelling episodes. For example, according to the United States National Library of Medicine in April 2023, the total number of genetic tests conducted in the U.S. was 35,000 in 2021, increasing to 37,271 in 2022. This rise in genetic disorders contributes to the growth of the berinert market.

The growth of healthcare spending is expected to fuel the expansion of the berinert market. Healthcare expenditure refers to the total financial resources allocated for medical services, infrastructure, pharmaceuticals, and related activities. The increase in healthcare spending is driven by an aging population, a higher prevalence of chronic and lifestyle-related diseases, a rise in genetic disorders, advancements in medical technology, and expanded access to healthcare. The expenditure on Berinert specifically involves costs related to managing hereditary angioedema (HAE), highlighting its role in reducing the severity of acute attacks and the need for hospitalization. For example, according to the Office for National Statistics in May 2023, household spending on hospital services in the UK rose from $7.68 billion in 2021 to $8.68 billion in 2022. As a result, the growing healthcare expenditure supports the berinert market.

A focus on expanding into new markets and improving formulations is driving the growth of berinert. A significant trend in the market is the development of more advanced treatment options, such as the Berinert 60 IU/kg subcutaneous injection, which can be administered twice a week at home, giving patients more convenience and control. This formulation is a lyophilized human C1-esterase inhibitor concentrate that can be reconstituted easily and injected subcutaneously by the patient. For instance, in September 2022, CSL Behring K.K., a biotechnology company based in Japan, received approval from the Ministry of Health, Labour and Welfare for the manufacturing and marketing of Berinert S.C. Injection 2000. This approval was based on the COMPACT study, which showed that patients receiving Berinert 60 IU/kg had significantly fewer acute hereditary angioedema (HAE) attacks - an average of 0.52 attacks per month - compared to 4.03 attacks per month in the placebo group, with a statistically significant difference (p < 0.001).

The key company operating in the berinert market is CSL Behring.

North America was the largest region in the berinert market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in berinert report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the berinert market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Berinert is a prescription medication containing C1 esterase inhibitor (human), a protein derived from human plasma. It is primarily used to treat hereditary angioedema (HAE), a rare genetic disorder that causes episodes of severe swelling in various parts of the body, such as the face, hands, feet, abdomen, or airway. Berinert works by replacing the deficient or malfunctioning C1 esterase inhibitor protein in patients with HAE. This protein plays a crucial role in regulating the complement and contact systems, which are involved in inflammation and blood vessel permeability.

The primary indications for berinert are hereditary angioedema (HAE) and acquired angioedema (AAE). HAE is a genetic condition that leads to episodes of severe swelling in the limbs, face, gastrointestinal tract, or airways due to low levels of C1 esterase inhibitor (C1-INH). Distribution channels for Berinert include hospital pharmacies, retail pharmacies, and online pharmacies. End users include adults, geriatric patients, and pediatric patients.

The berinert market research report is one of a series of new reports that provides berinert market statistics, including berinert industry global market size, regional shares, competitors with a berinert market share, detailed berinert market segments, market trends and opportunities, and any further data you may need to thrive in the berinert industry. This berinert market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The berinert market consists of sales of C1 esterase inhibitors, infusion pumps, autoinjectors, and prefilled syringes. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.